Liquidia utilizes a proprietary PRINT technology platform to design and manufacture highly precise micro- and nanoparticles and patterned films for applications in the life and materials science sectors. PRINT technology combines the precision of the microelectronics industry with the scalability of films manufacturing to produce custom shape and size-specific nanomaterials.
In the life sciences sector, Liquidia is using PRINT technology to develop Engineered Drug Therapies™ - precisely engineered micro- and nanoparticles - for the delivery of biological and small molecule therapeutics. Initial programs include siRNA delivery, inhaled therapeutics, and vaccines. Liquidia's ability to customize the shape, size, surface functionalization, and composition of particles enables increased efficacy of therapeutics.
Within the materials science sector, Liquidia is developing nano-patterned films for displays, solid state lighting, photovoltaics and related applications. The ability to replicate complex structures with nanometer fidelity, from a range of materials, and in a cost-effective manner will enable brighter, more energy efficient films and products for Liquidia's partners and consumers.
|
|
Recent News
June 22, 2009 - Liquidia presents at AAPS National Biotechnology Conference.  Details
June 11, 2009 - Liquidia appoints Dr. Thomas Templeman as SVP Details
April 28, 2009 - Liquidia presents data at NFID Conference on Vaccines Research Details
January 7, 2009 - Liquidia Announces Collaboration with Abbott to Develop siRNA Therapeutics Details
January 2009 - Liquidia to present at SPIE Photonics West in San Jose, CA
December 28, 2008 - Liquidia founder named 'Tar Heel of the Year' Details
October 30, 2008 - Liquidia to present at FPD International Forum in Yokohama, Japan Details
August 6, 2008 - Shape is key in nanomedicine Details
July 14, 2008 - Liquidia presents at Controlled Release Society Annual Meeting Details
June 25, 2008 - $500,000 Lemelson-MIT Prize awarded to Liquidia founder Details
| |
